Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 23, 2025
Doug Ruch Brings His 50-State Volunteer Mission to Project C.U.R.E. Chicago
GlobeNewswire
·
May 23, 2025
CHICAGO, IL, May 23, 2025 (GLOBE NEWSWIRE) -- CHICAGO, IL — May 23, 2025 — Project C.U.R.E. is proud to welcome Doug Ruch to its Chicago distribution center on Friday, May 23, as part of his mission to volunteer in all 50 states. Diagnosed with terminal …
Immix Biopharma Further Expands U.S. Clinical Sites for relapsed/refractory AL Amyloidosis Trial NEXICART-2
GlobeNewswire
·
May 23, 2025
– Patient enrollment exceeding expectations – – 14 U.S. sites actively enrolling; 10 U.S. sites added since last update – – Anticipate completing NEXICART-2 clinical trial ahead of schedule – LOS ANGELES, CA, May 23, 2025 (GLOBE NEWSWIRE) -- Immix …
Tilray Medical bringt die bekannte kanadische Cannabismarke Good Supply nach Deutschland
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Deutschland, May 23, 2025 (GLOBE NEWSWIRE) -- Tilray Medical („Tilray“), ein Geschäftsbereich von Tilray Brands, Inc. (NASDAQ: TLRY und TSX: TLRY) und ein weltweit führendes Unternehmen im Bereich des medizinischen Cannabis, das die …
Tilray Medical introduit Good Supply, la marque emblématique de cannabis canadienne, en Allemagne
GlobeNewswire
·
May 23, 2025
NEUMÜNSTER, Allemagne, 23 mai 2025 (GLOBE NEWSWIRE) -- Tilray Medical (« Tilray »), une division de Tilray Brands, Inc. (NASDAQ : TLRY et TSX : TLRY) et un leader mondial du cannabis thérapeutique qui permet aux patients et aux professionnels de santé de …
Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
GlobeNewswire
·
May 23, 2025
Positive CHMP opinion based on FELIX clinical trial of obecabtagene autoleucel (obe-cel) in adult patients with r/r B-ALL, demonstrating high and durable response rates and low toxicity Opinion follows FDA approval and MHRA conditional marketing …
Syncromune® Inc. Announces Publication of Abstract on SYNC-T® Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting
GlobeNewswire
·
May 23, 2025
Study Demonstrated 87% Overall Response Rate in Metastatic Prostate Cancer Patients Treated with SYNC-T, a First-in-Class In Situ Personalized Immunotherapy Platform Abstract published on podium presentation that will take place during the “Developmental …
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
GlobeNewswire
·
May 23, 2025
SOUTH SAN FRANCISCO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
GlobeNewswire
·
May 23, 2025
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group Women treated with IMNN-001 and standard of care chemotherapy plus PARP …
Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
GlobeNewswire
·
May 23, 2025
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on …
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewswire
·
May 23, 2025
SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), today announced that company management will participate in the Jefferies Global Healthcare Conference, taking place June 3-5, 2025 in New York, NY. Jefferies …
Safe Shot to Capitalize on Yerbae’s Strong Retail Presence & Distributor Network Following Acquisition
GlobeNewswire
·
May 23, 2025
Acquisition expected to increase Safety Shot annual revenue by 1000 percent over 2024 SCOTTSDALE, Ariz., May 23, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, …
SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
GlobeNewswire
·
May 23, 2025
– If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN – – Decision from European Commission expected in the third quarter of 2025 – STAMFORD, …
ScribeCanada to Showcase Care Team Support Solutions at Two Leading Healthcare Conferences this Spring
GlobeNewswire
·
May 23, 2025
VANCOUVER, B.C., May 23, 2025 (GLOBE NEWSWIRE) -- ScribeCanada, a care team support solutions provider, is excited to announce its participation in two leading healthcare conferences this spring. From May 23-28, ScribeCanada will attend the International …
BriaCell Abstracts Showcase Positive Survival and Clinical Benefit Data at ASCO 2025
GlobeNewswire
·
May 23, 2025
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in comparable metastatic breast cancer patients, with no treatment-related discontinuations Successful completion of the pivotal Phase 3 study may support …
Sol-Gel Reports First Quarter 2025 Results
GlobeNewswire
·
May 23, 2025
NESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025. Financial Results for the First Quarter Year …
Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas
GlobeNewswire
·
May 23, 2025
WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice …
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
GlobeNewswire
·
May 23, 2025
DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research …
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease
GlobeNewswire
·
May 23, 2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …
Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering
GlobeNewswire
·
May 23, 2025
ISELIN, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of an …
Inventiva reports 2025 First Quarter Financial Information¹
GlobeNewswire
·
May 23, 2025
Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral …